%PDF-1.4
%
115 0 obj
<>
endobj
112 0 obj
<>
endobj
176 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-03-01T11:25:15Z
2024-03-29T07:20:08-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T07:20:08-07:00
application/pdf
Heather
2004-114.may
uuid:35bad106-1dd2-11b2-0a00-2f0a278d5b00
uuid:35bad109-1dd2-11b2-0a00-1e0000000000
endstream
endobj
101 0 obj
<>
endobj
102 0 obj
<>
endobj
116 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 81 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 83 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 85 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 87 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 89 0 R/Type/Page>>
endobj
45 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 91 0 R/Type/Page>>
endobj
56 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 93 0 R/Type/Page>>
endobj
75 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 95 0 R/Type/Page>>
endobj
206 0 obj
[210 0 R]
endobj
207 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61.6916 736.1941 Tm
[(6.)-838.6 (Konttinen )36.8 (YT)73.9 (, )17.7 (T)69.9 (akagi M, Mandelin J, et al. )54.8 (Acid attack and )]TJ
1.5886 -1.25 Td
(cathepsin K in bone resorption around total hip replacement )Tj
0 -1.25 TD
(prosthesis. J Bone Miner Res 2001;16:1780-6.)Tj
-1.5886 -1.25 Td
[(7.)-838.6 (Haynes DR, Crotti )17.7 (TN, Potter )54.8 (AE, et al. )17.7 (The osteoclastogenic )]TJ
1.5886 -1.25 Td
[(molecules RANKL)-238.2 (and RANK are associated with periprosthetic)]TJ
T*
[(osteolysis. J Bone Joint Sur)17.7 (g Br 2001;83:902-1)36.8 (1.)]TJ
-1.5886 -1.25 Td
[(8.)-838.6 (Mandelin J, Li )17.7 (T)91.9 (-)0.2 (F)79.7 (, Liljestrom M, et al. Imbalance of)]TJ
1.5886 -1.25 Td
(RANKL/RANK/OPG system in interface tissue in loosening of)Tj
T*
[(total hip replacement implants. J Bone Joint Sur)17.7 (g Br )]TJ
0 Tc 0 Tw T*
[(2003;85:1)36.9 (196-201.)]TJ
-0.00011 Tc 0.0249 Tw -1.5886 -1.25 Td
[(9.)-838.6 (Itonaga I, Sabokbar )54.7 (A, Murray DW)91.7 (, )54.7 (Athanasou NA. Ef)17.7 (fect of)]TJ
1.5886 -1.25 Td
(osteoprotegerin and osteoprotegerin ligand on osteoclast formation)Tj
T*
[(by arthroplasty membrane derived macrophages. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:26-31.)Tj
-0.00011 Tc 0.02499 Tw -2.0885 -1.25 Td
[(10.)-838.6 (Lacey DL, )17.7 (T)35 (imms E, )17.7 (T)69.9 (an HL, et al. Osteoprotegerin ligand is a)]TJ
2.0885 -1.25 Td
[(cytokine that regulates osteoclast dif)17.7 (ferentiation and activation. Cell)]TJ
0 Tc 0 Tw T*
(1998;93:165-76.)Tj
-0.00011 Tc 0.02499 Tw -2.0517 -1.25 Td
[(1)36.8 (1)-0.1 (.)-838.6 (Y)99.8 (asuda H, Shima N, Nakagawa N, et al. Osteoclast dif)17.7 (ferentiation)]TJ
2.0517 -1.25 Td
(factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory)Tj
T*
[(factor and is identical to )17.7 (TRANCE/RANKL. Proc Natl )54.8 (Acad Sci)]TJ
0 Tc 0 Tw T*
[(USA)-220.1 (1998;95:3597-602.)]TJ
-0.00011 Tc 0.02499 Tw -2.0885 -1.25 Td
[(12.)-838.6 (Quinn JM, Elliott J, Gillespie MT)73.9 (, Martin )17.7 (TJ. )54.8 (A)-220.1 (combination of)]TJ
2.0885 -1.25 Td
[(osteoclast dif)17.7 (ferentiation factor and macrophage-colony )]TJ
T*
[(stimulating factor is suf)17.7 (ficient for both human and mouse osteoclast)]TJ
T*
(formation in vitro. Endocrinology 1998;139:4424-7.)Tj
-2.0885 -1.25 Td
[(13.)-838.6 (Simonet )17.7 (WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a)]TJ
2.0885 -1.25 Td
[(novel secreted protein involved in the regulation of bone density)64.8 (.)]TJ
T*
(Cell 1997;89:309-19.)Tj
-2.0885 -1.25 Td
[(14.)-838.6 (Y)99.8 (asuda H, Shima N, Nakagawa N, et al. Identity of )]TJ
2.0885 -1.25 Td
(osteoclastogenesis inhibitory factor \(OCIF\) and osteoprotegerin)Tj
T*
(\(OPG\): a mechanism by which OPG/OCIF inhibits )Tj
T*
(osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.)Tj
-2.0885 -1.25 Td
[(15.)-838.6 (Lee SK, Lorenzo JA. Parathyroid hormone stimulates )17.7 (TRANCE)]TJ
2.0885 -1.25 Td
(and inhibits osteoprotegerin messenger ribonucleic acid expression)Tj
T*
(in murine bone marrow cultures: correlation with osteoclast-like)Tj
T*
(cell formation. Endocrinology 1999;140:3552-61.)Tj
-2.0885 -1.25 Td
[(16.)-838.6 (Nagai M, Sato N. Reciprocal gene expression of osteoclastogenesis)]TJ
2.0885 -1.25 Td
[(inhibitory factor and osteoclast dif)17.7 (ferentiation factor regulates)]TJ
T*
(osteoclast formation. Biochem Biophys Res Commun)Tj
0 Tc 0 Tw T*
(1999;257:719-23.)Tj
-0.00011 Tc 0.02499 Tw -2.0885 -1.25 Td
[(17.)-838.6 (Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle )17.7 (WJ, Riggs)]TJ
2.0885 -1.25 Td
[(BL. )17.7 (The roles of osteoprotegerin and osteoprotegerin ligand in the)]TJ
T*
(paracrine regulation of bone resorption. J Bone Miner Res)Tj
0 Tc 0 Tw T*
(2000;15:2-12.)Tj
-0.00011 Tc 0.02499 Tw -2.0885 -1.25 Td
[(18.)-838.6 (T)69.9 (akayanagi H, Iizuka H, Juji )17.7 (T)74 (, et al. Involvement of receptor )]TJ
2.0885 -1.25 Td
[(activator of nuclear factor kappa-B ligand/osteoclast dif)17.7 (ferentiation)]TJ
T*
(factor in osteoclastogenesis from synoviocytes in rheumatoid )Tj
T*
[(arthritis. )54.8 (Arthritis Rheum 2000;43:259-69.)]TJ
-2.0885 -1.25 Td
[(19.)-838.6 (Heid CA, Stevens J, Livak KJ, )17.7 (W)39.9 (illiams PM. Real time quantitative)]TJ
2.0885 -1.25 Td
(PCR. Genome Res 1996;6:986-94.)Tj
-2.0885 -1.25 Td
[(20.)-838.6 (Boyle )17.7 (WJ, Simonet )17.7 (WS, Lacey DL. Osteoclast dif)17.7 (ferentiation and)]TJ
2.0885 -1.25 Td
(activation. Nature 2003;423:337-42.)Tj
-2.0885 -1.25 Td
[(21.)-838.6 (Whyte MP)110.7 (, Obrecht SE, Finnegan PM, et al. Osteoprotegerin )]TJ
2.0885 -1.25 Td
[(deficiency and juvenile Paget\325)54.8 (s disease. N Engl J Med)]TJ
0 Tc 0 Tw T*
(2002;347:175-84.)Tj
-0.00011 Tc 0.02499 Tw 30.9114 67.5 Td
[(22.)-838.6 (Cundy )17.7 (T)74 (, Hegde M, Naot D, et al. )54.8 (A)-220.1 (mutation in the gene)]TJ
2.0885 -1.25 Td
[(TNFRSF1)36.8 (1B encoding osteoprotegerin causes an idiopathic )]TJ
T*
[(hyperphosphatasia phenotype. Hum Mol Genet 2002;1)36.8 (1:21)36.8 (19-27.)]TJ
-2.0885 -1.25 Td
[(23.)-838.6 (Gelb BD, Shi GP)110.7 (, Chapman HA, Desnick RJ. Pycnodysostosis, a)]TJ
2.0885 -1.25 Td
[(lysosomal disease caused by cathepsin K deficiency)64.8 (. Science)]TJ
0 Tc 0 Tw T*
(1996;273:1236-8.)Tj
-0.00011 Tc 0.02499 Tw -2.0885 -1.25 Td
[(24.)-838.6 (Gravallese EM, Manning C, )17.7 (T)69.9 (say )54.8 (A, et al. Synovial tissue in)]TJ
2.0885 -1.25 Td
[(rheumatoid arthritis is a source of osteoclast dif)17.7 (ferentiation factor)54.8 (.)]TJ
T*
(Arthritis Rheum 2000;43:250-8.)Tj
-2.0885 -1.25 Td
[(25.)-838.6 (W)79.9 (ong BR, Rho J, )54.8 (Arron J, et al. )17.7 (TRANCE is a novel ligand of the)]TJ
2.0885 -1.25 Td
(tumor necrosis factor receptor family that activates c-Jun )Tj
T*
[(N-terminal kinase in )17.7 (T)-257.1 (cells. J Biol Chem 1997;272:25190-4.)]TJ
-2.0885 -1.25 Td
[(26.)-838.6 (W)39.8 (illard D, Chen )17.7 (WJ, Barrett G, et al. Expression, purification, and)]TJ
2.0885 -1.25 Td
(characterization of the human receptor activator of NF-kappa-B )Tj
T*
(ligand \(RANKL\) extracellular domain. Protein Expr Purif)Tj
0 Tc 0 Tw T*
(2000;20:48-57.)Tj
-0.00011 Tc 0.02499 Tw -2.0885 -1.25 Td
[(27.)-838.6 (Gori F)79.7 (, Hofbauer LC, Dunstan CR, Spelsber)17.7 (g )17.7 (TC, Khosla S, Riggs)]TJ
2.0885 -1.25 Td
[(BL. )17.7 (The expression of osteoprotegerin and RANK ligand and the)]TJ
T*
(support of osteoclast formation by stromal-osteoblast lineage cells)Tj
T*
(is developmentally regulated. Endocrinology 2000;141:4768-76.)Tj
-2.0885 -1.25 Td
[(28.)-838.6 (Thomas GP)110.7 (, Baker SU, Eisman JA, Gardiner EM. Changing)]TJ
2.0885 -1.25 Td
[(RANKL/OPG mRNA)-220.2 (expression in dif)17.7 (ferentiating murine primary)]TJ
T*
(osteoblasts. J Endocrinol 2001;170:451-60.)Tj
-2.0885 -1.25 Td
[(29.)-838.6 (Kitazawa S, Kitazawa R. Epigenetic control of mouse receptor )]TJ
2.0885 -1.25 Td
(activator of NF-kappa B ligand gene expression. Biochem Biophys)Tj
0 Tc T*
(Res Commun 2002;293:126-31.)Tj
-0.00011 Tc -2.0885 -1.25 Td
[(30.)-838.6 (Hofbauer LC, Lacey DL, Dunstan CR, Spelsber)17.7 (g )17.7 (TC, Riggs BL,)]TJ
2.0885 -1.25 Td
[(Khosla S. Interleukin-1 beta and tumor necrosis factor)19.7 (-alpha, but)]TJ
T*
(not interleukin-6, stimulate osteoprotegerin ligand gene expression)Tj
T*
(in human osteoblastic cells. Bone 1999;25:255-9.)Tj
-2.0885 -1.25 Td
[(31.)-838.6 (Hofbauer LC, Heufelder )54.8 (AE. Role of receptor activator of nuclear)]TJ
2.0885 -1.25 Td
[(factor)19.7 (-kappa B ligand and osteoprotegerin in bone cell biology)64.8 (. )]TJ
0 Tc T*
(J Mol Med 2001;79:243-53.)Tj
-0.00011 Tc -2.0885 -1.25 Td
[(32.)-838.6 (T)69.9 (akahashi N, )54.8 (Akatsu )17.7 (T)74 (, Udagawa N, et al. Osteoblastic cells are)]TJ
2.0885 -1.25 Td
(involved in osteoclast formation. Endocrinology 1988;123:2600-2.)Tj
-2.0885 -1.25 Td
[(33.)-838.6 (Mandelin J, Liljestrom M, Li )17.7 (T)91.8 (-)0.2 (F)79.7 (, et al. Pseudosynovial fluid from)]TJ
2.0885 -1.25 Td
(loosened total hip prosthesis induces osteoclast formation. )Tj
T*
(J Biomed Mater Res 2005;73B: \(in press\).)Tj
-2.0885 -1.25 Td
[(34.)-838.6 (Crotti )17.7 (TN, Smith MD, Findlay DM, et al. Factors regulating )]TJ
2.0885 -1.25 Td
(osteoclast formation in human tissues adjacent to peri-implant bone)Tj
T*
(loss: expression of receptor activator NF kappa B, RANK ligand)Tj
T*
(and osteoprotegerin. Biomaterials 2004;25:565-73.)Tj
-2.0885 -1.25 Td
[(35.)-838.6 (Garnero P)110.7 (, Borel O, Byrjalsen I, et al. )17.7 (The collagenolytic activity of)]TJ
2.0885 -1.25 Td
(cathepsin K is unique among mammalian proteinases. J Biol Chem)Tj
0 Tc 0 Tw T*
(1998;273:32347-52.)Tj
-0.00011 Tc 0.02499 Tw -2.0885 -1.25 Td
[(36.)-838.6 (Hou )17.7 (WS, Li Z, Gordon RE, et al. Cathepsin K is a critical protease)]TJ
2.0885 -1.25 Td
[(in synovial fibroblast-mediated collagen degradation. )54.8 (Am J Pathol)]TJ
0 Tc 0 Tw T*
(2001;159:2167-77.)Tj
-0.00011 Tc 0.02499 Tw -2.0885 -1.25 Td
[(37.)-838.6 (Hou )17.7 (WS, Li )17.7 (W)91.8 (, Keyszer G, et al. Comparison of cathepsins K and)]TJ
2.0885 -1.25 Td
(S expression within the rheumatoid and osteoarthritic synovium.)Tj
T*
(Arthritis Rheum 2002;46:663-74.)Tj
ET
0 0 0 1 K
53.964 76.5 m
558.972 76.5 l
S
0 0 0 0 k
52.822 69.665 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 53.8216 56.7343 Tm
(720)Tj
ET
0 0 0 0 k
356 69.665 203 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 56.7343 Tm
(The Journal of Rheumatology 2005; 32:4)Tj
ET
0 0 0 0 k
/GS0 gs
103.631 82.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.631 82.25 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
95 0 obj
<>stream
8;Z\6!HQ(#%.jK`aEMf%YU"i-1bH>o/mbaG82.J'b:2PXs(#`\?Jhs0nRoo2A+dKQ
`E.$)Dt`$[WB9M&CNU)aadQX:mLFTgHs_BSEVoZFK*T/+Fsc?23H@iK*lXO``H^=d
"0Y:)>KsGLAt;ET)o0U9=9h>ZeEfO"[=fT:7:A`En!QFV%LMBC?B*Jh$O,aA/f
m11]tW(ipr&EkgRB^dS<>sfmVQlI#ffL"IPLJ->[Lk3%0Lr]i:D]AEP?aU3IM$0Z^
NTTn2&q_>6,u>p#];S]-*d[rkD`,Zi:3SI=k\I:`I8jp\PoNV#AB@]6"r(>FHVEI#
DosP?*5Q4J33:87i?
1M"X+=.2nNC?\h=Q?=k[$Sb.D"lNQ[Kal;cegSLH-^1`r8/
i:ad7EN7X]Usem9A@FH]p=Nl9]l/)3L0ea>^FQHG[FdJ:[_GR"p8@:j!,>qQQi~>
endstream
endobj
99 0 obj
[/Indexed/DeviceRGB 255 98 0 R]
endobj
98 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
134 0 obj
<>
endobj
119 0 obj
<>
endobj
159 0 obj
<>
endobj
181 0 obj
<>
endobj
118 0 obj
<>
endobj
154 0 obj
<>stream
HtUkPWa 6B+bdĀ@#
0(00"0"ĀȀ#QэZD]\UfIzYw?[[ԭsw="DS"#"V-ISgR5Iż"~ψyOGflSϺz`˾_$8 u@U2r5ͭ=s>rm3YI~\`s&lЄ
Bjn]!Sf'i:^Nq\D6Yݍ9SqzU:MiStmfNͅFpyZ=p]MFר
aDD$7l-txa&+°~İB&p,ۋٰKV!:$!ڡaLNlvtq48v|!=wIQZ"}Tt͙v9#B7'4((kqsu;.s/t!&H<=z{{'y_(+;Nӳ۳CV¨8p<@y
{AJnͯQ$P{2Bl'2
f8"XK{ni5ɘxvUCn^W"kOOhTTL2
/1`C;|F!-aZq 5Xkh